Kiniksa Pharmaceuticals International (KNSA) Interest & Investment Income (2017 - 2026)
Kiniksa Pharmaceuticals International's (KNSA) quarterly Interest & Investment Income came in at -$715000.0 in Q2 2026, down 738.39% YoY from $112000.0 in Q2 2025, and down 11.72% on a QoQ basis from -$640000.0 in Q1 2026.
Kiniksa Pharmaceuticals International (KNSA) Interest & Investment Income (2017 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International (KNSA) has 10 years of Interest & Investment Income data on file, last reported at -$715000.0 in Q2 2026.
- Quarterly Interest & Investment Income fell 738.39% year-over-year to -$715000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$1.3 million (down 1823.38% YoY) and the FY2025 annual result came in at $138000.0, up 181.66% from the prior year.
- Interest & Investment Income fell to -$715000.0 in Q2 2026, from -$640000.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $130000.0 in Q4 2025 to a low of -$715000.0 in Q2 2026.
- A 5-year average of -$73000.0 and a median of -$8000.0 in 2023 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2024 — Interest & Investment Income soared 735.71% — and 2026, when it slumped 31900.0%.
- Tracing KNSA's Interest & Investment Income over 5 years: stood at $114000.0 in 2022, then tumbled by 93.86% to $7000.0 in 2023, then tumbled by 1842.86% to -$122000.0 in 2024, then jumped by 206.56% to $130000.0 in 2025, then slumped by 650.0% to -$715000.0 in 2026.
- The last three Interest & Investment Income figures came in at -$715000.0 (Q2 2026), -$640000.0 (Q1 2026), and $130000.0 (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 154.39 Mn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 31.50 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 12.40 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Kiniksa Pharmaceuticals International | 6.09 Bn | 5.56 Bn | 220.03 Mn | -715,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -715,000.00 |
| Mar 31, 2026 | -640,000.00 |
| Dec 31, 2025 | 130,000.00 |
| Sep 30, 2025 | -102,000.00 |
| Jun 30, 2025 | 112,000.00 |
| Mar 31, 2025 | -2,000.00 |
| Dec 31, 2024 | -122,000.00 |
| Sep 30, 2024 | 89,000.00 |
| Jun 30, 2024 | -77,000.00 |
| Mar 31, 2024 | -59,000.00 |
| Dec 31, 2023 | 7,000.00 |
| Sep 30, 2023 | -14,000.00 |
| Jun 30, 2023 | -42,000.00 |
| Mar 31, 2023 | 11,000.00 |
| Dec 31, 2022 | 114,000.00 |
| Sep 30, 2022 | 20,000.00 |
| Jun 30, 2022 | 13,000.00 |
| Mar 31, 2022 | -37,000.00 |
| Dec 31, 2021 | -52,000.00 |
| Sep 30, 2021 | -72,000.00 |